Autopsy report · NCT04343755

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

“Lack of eligible patients due to change in standard therapy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• 52 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Hackensack Meridian Health

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Convalescent Plasma

Participants

52

Sites

1

Countries

United States

Trials that died the same way

• Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
  “Lack of potential study subjects due to a change of standard of care treatment outside of clinical trials.” (72% match in meaning)
• RAPA-501-Allo Therapy of COVID-19-ARDS
  “Change in eligible patient population” (66% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (66% match in meaning)
• The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
  “Lack of eligible patients” (65% match in meaning)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.